Table 1.

Dose interruptions and reductions in initial registration trials for small-molecule KIs approved for oncology indications with PMC or PMR to study alternate doses (percentage of patients on registration studies)

DrugDose interruptionDose reductionDose interruption or delay
Erlotinib62%19%NA
Vandetanib47%49%80%
CabozantinibNA79%86%
Ponatinib66%52%74%
Ceritinib69%59%71%
IdelalisibNA34%53%
Lenvatinib56%68%90%